Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism
Authors:
- 23 March 2020
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 47 (11) , 2656-2665
Abstract
Purpose It is challenging to differentiate unilateral aldosterone-producing adenoma (APA) from bilateral idiopathic adrenal hyperplasia (IAH) and nonfunctional adrenal adenoma (NFA) in primary aldosteronism (PA). In a first primarily ex vivo study detection, CXC chemokine receptor type 4 (CXCR4) expression has been shown to be a valuable tool for the detection of APA. In this study, we aimed to clinically evaluate CXCR4 imaging with 68Ga-pentixafor PET/CT for detecting APA. Methods We prospectively recruited 36 patients with clinical suspicion of PA. All patients underwent 68Ga-pentixafor PET/CT. Positive lesions were defined based on higher tracer uptake in adrenal nodular(s) shown on CT than the normal adrenal. These lesions were referred for adrenalectomy subsequently. All patients received clinical follow-up. Semi-quantitative analysis using maximum standardized uptake value (SUVmax), lesion-to-liver ratio (LLR), and lesion-to-contralateral ratio (LCR) has also been performed. PET/CT results were correlated with clinical presentation and follow-up. Results Thirty-nine adrenal lesions in 36 patients were found; 25 APA, 4 IAH, and 10 NFA according to histopathology and clinical assessment. Sensitivity, specificity, and accuracy of 68Ga-pentixafor PET/CT in distinguishing APA by visualization were 100%, 78.6%, and 92.3% respectively. The SUVmax of APA (21.34 ± 9.41, n = 25) was significantly higher than that of non-APA lesions (6.29 ± 2.10, n = 14, P < 0.0001). An optimal threshold of SUVmax = 11.18 was determined for predicting APA with a sensitivity of 88.0%, specificity of 100%, and an accuracy of 92.3%. A cutoff value for LCR of 2.12 yielded a sensitivity of 100% and a specificity of 92.9%, whereas a cutoff value for LLR of 2.36 reached at both 100% of sensitivity and specificity. All patients with (removed) positive lesions benefited from surgery. Conclusion 68Ga-Pentixafor PET/CT may be used to non-invasively detect APA in PA patients.Keywords
This publication has 21 references indexed in Scilit:
- The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2016
- Nuclear imaging in the diagnosis of primary aldosteronismCurrent Opinion in Endocrinology, Diabetes and Obesity, 2015
- [123I]Iodometomidate Imaging in Adrenocortical CarcinomaThe Journal of Clinical Endocrinology & Metabolism, 2013
- Histopathological Diagnosis of Primary Aldosteronism Using CYP11B2 ImmunohistochemistryThe Journal of Clinical Endocrinology & Metabolism, 2013
- Functional Characterization of Adrenal Lesions Using [123I]IMTO-SPECT/CTThe Journal of Clinical Endocrinology & Metabolism, 2013
- Primary hyperaldosteronism: challenges in subtype classificationBMC Research Notes, 2012
- Evaluation of the Sensitivity and Specificity of11C-Metomidate Positron Emission Tomography (PET)-CT for Lateralizing Aldosterone Secretion by Conn's AdenomasThe Journal of Clinical Endocrinology & Metabolism, 2012
- Gene expression profiles in aldosterone-producing adenomas and adjacent adrenal glandsEuropean Journal of Endocrinology, 2011
- 131I-6β-Iodomethyl-19-Norcholesterol SPECT/CT for Primary Aldosteronism Patients with Inconclusive Adrenal Venous Sampling and CT ResultsJournal of Nuclear Medicine, 2009
- Role for adrenal venous sampling in primary aldosteronismSurgery, 2004